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Dear Editor,
Caplacizumab (Cablivi®) is a novel anti-von Willebrand fac-
tor (vWF) nanobody approved for the treatment of acquired
thrombotic thrombocytopenic purpura (aTTP) [1]. A single-dose
(10 mg) caplacizumab is given intravenously before starting plas-
ma exchange (PEX), followed by daily (10 mg) SC injections for
up to 30 days after last PEX. We collected clinical data of 60
patients between 2018 and 2019 [2, 3]. In 7 cases (> 10%), we
observed local injection site reactions appearing 4 days to 4weeks
after the start of the caplacizumab treatment. These skin reactions
caused great uncertainty leading to an altered, off-label manage-
ment in 5 cases and might interfere with the patients’ treatment
outcome. The skin reactions presented as erythema with hyperre-
activity around the injection site with hyperemia and itching
(Fig. 1). The findings developed sooner and more pronounced
with subsequent injections even at different sites. There were no
significant changes in the eosinophilia count, IgE levels, or C-
reactive protein. Importantly, the reactions had no measurable
impact on drug efficacy as vWF activity remained suppressed.
The local reactions did not respond to anti-histaminic or high-dose
glucocorticoid treatment. All patients were still on a steroid-
tapering regime with dosages ranging from 12.5 to 80 mg/day
prednisolone. In one patient, the caplacizumab dosing was not
altered but prednisolone increased to 30 mg/day. In two other
patients, caplacizumab was first continued and later extended to
a q2 dosing regimen with daily prednisolone (30 mg). In another
patient, caplacizumabwas briefly interrupted before being contin-
ued in an unchanged alternate dosing regimen and 50 mg of
prednisolone in addition to each injection. Caplacizumab was
discontinued in 3/6 patients. In one of these 3 patients, an aTTP
relapse occurred after stopping the treatment, and caplacizumab
was restarted on a q2 dosing regimen together with prednisolone
(12.5 mg/day). After discontinuation of caplacizumab, the skin
reactions slowly disappeared. In patients with ongoing treatment,
the skin reactions peaked before slowly resolving over several
weeks independent of any of the abovementioned measures. All
patients had a full recovery from aTTP.
In the HERCULES trial, urticaria and local injection site pain
were reported as an adverse event in 16.9%and1.4%ofpatients in
the caplacizumab arm and 6.8% and 5.5% in the placebo arm [1]
potentiallyasareaction to the freshfrozenplasmaand thePEX.[4].
In our patients, the erythema always occurred several days/weeks
after the cessationofPEX.Pre-existingallergieswerenot reported.
One excipient in the formulation of Cablivi is Polysorbate
80 besides sucrose, citric acid, and sodium citrate.
Polysorbates are often added to stabilize new biotherapeutics
such as new formulations of erythropoeitin or PCSK9i [5, 6].
Polysorbates have the potential to activate complement and
may cause acute hypersensitivity reactions as well as anaphy-
lactoid reactions and local skin reactions [7]. Further studies
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are required to delineate the role of Polysorbate 80 and a
causal relationship for the observed symptoms.
We suggest monitoring patients closely for evolving local
skin reactions and that caplacizumab should only be prema-
turely discontinued in cases with systemic side effects (hypo-
tension, wheezing, generalized rash). Extending the dosing
interval to every other day using vWF activity measurement
to guide the treatment appears to be a safe and feasible thera-
peutic option in patients with a local skin reaction [3].
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Fig. 1 Local skin reaction with
different time points after
injection (upper panel). It takes
about 7–14 days before lesions
have disappeared (lower panel)
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